R.s. Surgipharm Private Limited — Rituximab Exporter Profile
Indian Pharmaceutical Exporter · #9 for Rituximab · $118.2K export value · DGFT Verified
R.s. Surgipharm Private Limited is the #9 Indian exporter of Rituximab with $118.2K in export value and 63 verified shipments. R.s. Surgipharm Private Limited holds a 0.6% market share in Rituximab exports across 2 countries. The company exports 7 pharmaceutical products worth $431.6K across 2 therapeutic categories.
R.s. Surgipharm Private Limited — Rituximab Export Profile: Buyers & Destinations
Where Does R.s. Surgipharm Private Limited Export Rituximab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| KENYA | $114.4K | 58 | 96.8% |
| CAMEROON | $3.8K | 5 | 3.2% |
R.s. Surgipharm Private Limited exports Rituximab to 2 countries. The largest destination is KENYA accounting for 96.8% of R.s. Surgipharm Private Limited's Rituximab shipments. These destinations reflect R.s. Surgipharm Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Rituximab from India?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| JSC R-PHARM | RUSSIA | $550.0K | 11 |
| ABC PHARMA SERVICES (PVT) LTD | SRI LANKA | $430.6K | 10 |
| DR.REDDYS LABORATORIES PHILIPPINES | PHILIPPINES | $368.9K | 8 |
| STATE PHARMACEUTICALS CORPORATION | SRI LANKA | $300.0K | 6 |
| LABORATORIOS LEGRAND S A | COLOMBIA | $250.0K | 5 |
| LABORATORIOS LEGRAND S.A | COLOMBIA | $250.0K | 5 |
| STATE PHARMACEUTICALS CORPORATION O | SRI LANKA | $150.0K | 3 |
| XXAROXXPHAXXA SXX DXXC V | MEXICO | $100.0K | 2 |
| DROGUERIA MK LAB S.A.C | PERU | $100.0K | 2 |
| SYNTEGON TECHNOLOGY GMBH | GERMANY | $100.0K | 2 |
India's Rituximab is purchased by 292 buyers worldwide. The top buyer is JSC R-PHARM (RUSSIA), followed by ABC PHARMA SERVICES (PVT) LTD and DR.REDDYS LABORATORIES PHILIPPINES.
What Is India's Total Rituximab Export Value and How Much Does R.s. Surgipharm Private Limited Contribute?
India exported $9.4M worth of Rituximab through 1,215 shipments from 164 suppliers to 104 countries, serving 292 buyers globally. R.s. Surgipharm Private Limited contributes $118.2K to this total, accounting for 0.6% of India's Rituximab exports. R.s. Surgipharm Private Limited ships Rituximab to 2 countries through 0 buyers.
What Is the Average Shipment Value for R.s. Surgipharm Private Limited's Rituximab Exports?
R.s. Surgipharm Private Limited's average Rituximab shipment value is $1.9K per consignment, based on 63 shipments totaling $118.2K. The largest destination is KENYA (96.8% of R.s. Surgipharm Private Limited's Rituximab exports).
How Does R.s. Surgipharm Private Limited Compare to Other Indian Rituximab Exporters?
R.s. Surgipharm Private Limited ranks #9 among 164 Indian Rituximab exporters with a 0.6% market share. The top 3 exporters are RELIANCE LIFE SCIENCES PRIVATE LIMITED ($4.1M), DR.REDDY'S LABORATORIES LTD ($3.2M), DR REDDYS LABORATORIES LIMITED ($550.0K). R.s. Surgipharm Private Limited processed 63 shipments to 2 destination countries.
What Rituximab Formulations Does R.s. Surgipharm Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| (HARMLESS MEDICINES FOR INJECTABLEAND CAPSULES AND TABLETS)Rituximab Injection 500mg/50ml(1 Vial) | $25.6K | 5 |
| RITUXIMAB 500MG INJ (1 VIAL) | $21.3K | 16 |
| RITUXIMAB INJECTION IP 500MG/50ML (UNIT PACK : 1 VIAL) | $13.1K | 3 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS)RITUXIMAB 500MG INJ 1 VIALNOS | $8.6K | 2 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS) RITUXIMAB CONCENTRATE FOR SOLUTIONFOR INFUSION 500MG-1 VIAL | $7.0K | 2 |
| RITUXIMAB 500MG INJ(1 VIAL) | $5.8K | 1 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS)RITUXIMAB INJECTION IP 500MG/50ML 1VIAL | $4.7K | 2 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS) RITUXIMAB 500MG/50ML INJECTION | $4.2K | 1 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS) RITUXIMAB 500MG INJ1 VIALNOS | $3.3K | 2 |
| (HARMLESS MEDICINES INJECATABLE AND TABLETS) RITUXIMAB 500MG INJECTION(1 VIAL)NOS | $3.2K | 1 |
R.s. Surgipharm Private Limited exports 30 distinct Rituximab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is (HARMLESS MEDICINES FOR INJECTABLEAND CAPSULES AND TABLETS)R with 5 shipments worth $25.6K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does R.s. Surgipharm Private Limited Compare to Nearest Rituximab Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 6 | INVEX HEALTH PRIVATE LIMITED | $150.0K | 3 | 2 | $50.0K |
| 8 | J.A. UNITED EXPORTS PRIVATE LIMITED | $122.3K | 20 | 4 | $6.1K |
| 9 | R.S. SURGIPHARM PRIVATE LIMITED ★ | $118.2K | 63 | 2 | $1.9K |
| 10 | RMPL PHARMA LLP | $92.7K | 55 | 9 | $1.7K |
| 11 | PNT PHARMA | $86.7K | 12 | 1 | $7.2K |
R.s. Surgipharm Private Limited ranks #9 among 164 Indian Rituximab exporters. Average shipment value of $1.9K compared to the market average of $57.4K. The closest competitors by value are INVEX HEALTH PRIVATE LIMITED and J.A. UNITED EXPORTS PRIVATE LIMITED.
Which Indian Ports Ship Rituximab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 389 | 32.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 325 | 26.7% |
| Bombay Air | 85 | 7.0% |
| Bombay Air Cargo | 58 | 4.8% |
| HYDERABAD ACC (INHYD4) | 46 | 3.8% |
| DELHI AIR CARGO ACC (INDEL4) | 45 | 3.7% |
| DELHI AIR | 35 | 2.9% |
| AHEMDABAD AIR | 26 | 2.1% |
What Other Advanced Oncology Products Does R.s. Surgipharm Private Limited Export?
R.s. Surgipharm Private Limited also exports these advanced oncology products. Each links to the detailed product page.
About R.s. Surgipharm Private Limited
R.s. Surgipharm Private Limited exports 7 products worth $431.6K. Beyond Rituximab, top products include Bevacizumab, Everolimus, Cabazitaxel, Carfilzomib, Regorafenib. View the complete R.s. Surgipharm Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Rituximab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Rituximab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: R.s. Surgipharm Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 63 individual customs records matching R.s. Surgipharm Private Limited exporting Rituximab, covering 30 formulations to 2 countries via 0 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 292+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Rituximab Export Data from R.s. Surgipharm Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for R.s. Surgipharm Private Limited's Rituximab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
R.s. Surgipharm Private Limited
Full Company Profile →
7 products · $431.6K total trade · 2 categories
Rituximab Stats
Company Overview
Top Products by R.s. Surgipharm Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for R.s. Surgipharm Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rituximab. For current shipment-level data, contact TransData Nexus.